211 Saint Francis Drive • Entrance 6 Cape Girardeau, MO 63703

573-331-3000 • www.sfmc.net

Free Community Lung Cancer Screenings

Cancer InstituteProgram Overview Report

2015-2016

Lung cancer is the second-most diagnosed cancer in both men and women and the leading cause of cancer deaths in the country, with a five-year survival rate of less than 18 percent. In 2013, the Cancer Institute and community partners worked together to complete a CHNA.

Once seeing the need, Saint Francis quickly implemented free low-dose CT lung cancer screenings to patients each quarter. In 2016, when an additional CHNA indicated lung cancer as one of the top four cancers in the region, the Medical Center began offering screenings to patients monthly. This essential health exam, which typically costs $300-$500 and is not always covered by insurance, has been well received. Screening appointments, which fill quickly, are communicated to area residents through our website, digital outdoor boards, ads, fliers and local TV stations’ web banners.

Number Of Lung Screening Patients

% Of Patients Requiring Additional Diagnostic Imaging

271 8.49%

2013 2014 2016 TOTAL20150

50

100

150

200

250

57

Num

ber

of L

ung

Scr

eeni

ng P

atie

nts

Percentage of Patients RequiringAdditional Diagnostic Workup

52 51

94

254

18.46%7.14% 5.88% 4.04% 7.01%

Accredited by the American College of Surgeons Commission on Cancer (CoC)

Saint Francis is accredited through the American College of Surgeons Commission on Cancer (CoC), identifying our commitment to providing high-quality, patient-centered care for all patients, allowing access to the services needed from initial diagnosis through remission.

Through this accreditation in 2016, Saint Francis Cancer Institute offered:

• Prevention programs, including “Kick Cancer to the Curb,” a well-rounded approach to all things related to cancer; and “Spot Me Program,” focused on skin cancer prevention

• Monitoring compliance with evidence-based guidelines through Microsatellite Instability Testing on all colon cancer pathology specimens

• Quality studies, including a study to determine if patients who test positive for the BRCA gene are followed per NCCN guidelines; and a study to

determine if all ovarian cancer patients are tested for the BRCA gene or referred for genetic counseling (per NCCN guidelines)

• Quality improvements, including MSI testing, BRCA gene testing for ovarian cancer patients and following BRCA gene positive patients (per NCCN guidelines)

• Accountability measure and quality improvement outcomes were measured by our Cancer Program Practice Profile Reports or CP3R. This information is an additional layer of quality data to enhance the cancer-fighting toolbox

The CP3R(v3) provides feedback to our programs to*:

• Improve the quality of data across several disease sites

• Foster pre-emptive awareness to the importance of charting and coding accuracy

• Improve clinical management and coordination of patient care in the multidisciplinary setting

*Source: https://www.facs.org/quality-programs/cancer/coc

Saint Francis Healthcare System is a regional leader in the battle against cancer, bringing new techniques, ideas and hope for a brighter future.

Our skilled and compassionate cancer experts promote wellness, fight disease and advance medicine by delivering a standard of quality and service that has garnered national recognition and earned the trust of patients and physicians alike.

Saint Francis Medical Center in Cape Girardeau, Mo., is home to the region’s only dedicated Heart Hospital Cancer Institute where patients have access to the most advanced medicines, progressive therapies and state-of-the-art technology – all under one roof. Critical prevention and support services are also an integral part of treatment for patients and their family members at the Cancer Institute.

Our cancer team is committed to offering the latest advances and best outcomes to cancer patients across the region. That means using the most powerful resources and strategies available. We offer a complete range of cutting-edge cancer technologies and services, including:

• da Vinci® S HD™ Surgical System, with more than 1,000 cancer surgeries performed by gynecological oncologist Joseph H. Jacob, MD, FACOG, FACS

• CyberKnife® Robotic Radiosurgery System, the only one in the region

• 35-bay chemotherapy infusion center designed by patients• Intensity-modulated radiation therapy (IMRT)• Image-guided radiation therapy (IGRT)

• Advanced diagnostics, including PET/CT, 64-slice CT, open 1.5 Tesla MRI, tomosynthesis and digital mammography

• Minimally invasive pelvic laparoscopy• Biological drug therapy• Immunotherapy• Electronic brachytherapy• Cancer rehabilitation• Pain management• Lymphedema management• Food and nutrition service

To best serve our patients in outlying areas in response to our Community Health Needs Assessment (CHNA), we’ve expanded our cancer services in Sikeston, Perryville and Dexter.

In addition to our technologies and services, we are working with a leader in cancer care, The University of Texas MD Anderson Cancer Center, to raise the standard of care in our community and beyond.

The American College of Surgeons Commission on Cancer (CoC) has accredited Saint Francis through 2017. This accreditation proves Saint Francis’ commitment to providing high-quality, patient-centered care for all patients, allowing access to the services needed from initial diagnosis through remission.

MD Anderson Cancer Network® Affiliation

Occurrence of Cancer by Site and Gender

Oral Cavity & Pharynx - 9 (3%)

Lung & Bronchus - 88 (28%)

Pancreas - 6 (2%)

Kidney & Renal Pelvis - 15 (5%)

Urinary Bladder - 21 (7%)

Colon & Rectum - 43 (14%)

Prostate - 45 (14%)

Non-Hodgkin Lymphoma - 11 (4%)

Melanoma of the Skin - 10 (3%)

Leukemia - 3 (1%)

All Other Sites - 63 (20%)

Thyroid - 24 (5%)

Lung and Bronchus - 67 (15%)

Breast - 120 (26%)

Kidney & Renal Pelvis - 13 (3%)

Ovary - 16 (4%)

Uterine Corpus - 58 (13%)

Colon & Rectum - 33 (7%)

Non-Hodgkin Lymphoma - 22 (5%)

Melanoma of the Skin - 4 (1%)

Leukemia - 5 (1%)

All Other Sites - 92 (20%)

Males Females

A total of 768 cases were entered into the database in 2015. The lung was the No. 1 site for disease with 155 cases, 88 men and 67 women. Breast was second with 120 female cases and “other” was third, 63 males and 92 females. Corpus uteri was fourth highest with 58 cases added in 2015 and colorectal cancer was the fifth site with 76 cases, 43 males and 33 females.

* 2015 analytical data

A program of The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Network® affiliates with other oncology providers – such as Saint Francis – to promote quality management and best practices in cancer care. Saint Francis is the only facility in the region selected to be an MD Anderson Cancer Network-certified member hospital. Through this unique affiliation, Saint Francis is raising the level of cancer care for patients by using a multidisciplinary team approach and offering powerful cancer-fighting resources not available elsewhere in the region. Patients are able to benefit from the latest advances, decades of research and proven best practices in cancer care, all of which help contribute to the best possible outcomes.

Our skilled oncologists and surgeons are recognized experts in cancer care and were chosen to complete a rigorous evaluation process, ultimately earning the distinction of being MD Anderson Cancer Network-certified physicians. As a result, they have access to evidence-based treatment protocols and processes developed by MD Anderson – the nation’s leader in cancer care. MD Anderson is one of the world’s most respected centers devoted exclusively to cancer care, research, education and prevention and is consistently ranked by U.S. News & World Report in their “Best Hospitals” survey, as the nation’s No. 1 cancer treatment center.

Five-Year Survival

Pictured from left to right: Mark A. Meadors, DO, Oncologist; Carlos Robles, MD, Oncologist/Hematologist; Tapan Roy, MD, FACR, Radiation Oncologist; Joseph H. Jacob, MD, FACOG, FACS, Gynecologic Oncologist; Prem Sobti, MD, Oncologist/Hematologist

Observed Survival by Best CS/AJCC Stage Report 2005-2010 Breast Cancer - Analytical Cases (Kaplan-Meier)

0

0.2

0.4

0.6

0.8

1.0

Year 0

Stage 0

Year 1 Year 2 Year 3 Year 4 Year 5

Stage IStage IIStage IIIStage IV

0

0.2

0.4

0.6

0.8

1.0

Year 0 Year 1 Year 2 Year 3 Year 4 Year 5

0

0.2

0.4

0.6

0.8

1.0

Year 0 Year 1 Year 2 Year 3 Year 4 Year 5

Our MD Anderson Cancer Network®-certified physicians